On February 16, just a week after Arshdeep Singh died on February 8, Havildar Naresh Kumar consented to donate his ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Researchers have found in a new study that higher dietary niacin intake was associated with lower all-cause mortality risk in ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

The Army transplant team of Command Hospital Western Command successfully harvested Arshdeep Singh’s liver, kidney, pancreas, ...

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OS ...

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Researchers have found in a new study that a high TyG index predicts poor clinical outcomes and may serve as a novel ...